• Define NGS-based diagnostic product development strategies.• Support regulatory submission for diagnostics of cancer and infectious diseases.• Support design and development of immunosequencing IVD assays and kits.• Ensure compliance with regulations in development and validation; ensure technology transfer to Production and CLIA labs.

• Lead diagnostics product development for targeted oncology therapeutics, including analytical and clinical validation• Work with regulatory affair and quality assurance for PMA and 510(k) submission to FDA• Managed multiple translational research programs including gene expression profiling for immune response in tumor microenvironment

• Led metastatic breast cancers program with a focus on biomarker and drug resistance.• Single cell profiling on cellular responses to tumor microenvironment for improved cancer therapeutics and diagnostics.• Initiated and led the assay development effort for multi-organizational drug discovery programs for Neurodegenerative Diseases.• high content imaging, single cell analysis

• Led research effort and managed projects for small molecule drug discovery targeting chronic kidney disease and fibrosis as well as glaucoma.• Identified and validated disease target genes with in vitro functional assays.• Supervised the in vivo team to establish animal models for kidney disease.• Integrated and collaborated on experimental designs, data analysis and interpretation across disciplines and departments.

• Led therapeutic siRNA discovery project and the in vitro team for Drug Delivery Systems (DDS) project, coordinated inter-department collaboration on DDS project.• Built and managed a new in vitro team dedicated to automated HTS platforms for siRNA DDS.• Proposed and implemented strategic plans for validating novel targets in liver diseases, evaluating new biological entities and investigating their mechanism of action.• Designed and identified therapeutic siRNA molecules targeting liver fibrosis (moved to clinical trial).• Developed screening and validation assays for siRNA DDS.

• Identified and characterized small molecule drug candidates targeting cancers and neurodegenerative diseases• Conceptualized and developed cell-based and biochemical assays on high throughput (HTS) and ultra HTS platforms for small molecule and genomic screening of multiple signaling pathways

Molecular mechanism of peripheral oscillation, cell-based biological clock models, real-time bioluminescence imaging.